Rempex remix

How track record of anti-infectives start-up Qpex’s team attracted NEA-led syndicate

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio.

The start-up’s management team includes former executives from Medicine Co.’s infectious

Read the full 462 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE